Shanghai Kaimo Biopharmaceutical

Shanghai Kaimo Biopharmaceutical is a China-based biotechnology company focused on the research, development, and commercialization of innovative recombinant protein drugs and monoclonal antibodies. The company specializes in oncology and ophthalmology, with a portfolio that includes treatments for various solid tumors and retinal diseases. Kaimo Biopharmaceutical operates integrated R&D and manufacturing facilities that comply with international GMP standards, enabling the production of high-quality biologics for the domestic and global markets. Their lead products often target pathways involved in apoptosis and angiogenesis, aiming to provide effective therapeutic options for life-threatening and chronic conditions.